Agilus Diagnostics and Lucence announced a strategic partnership on 24 February 2025 to integrate liquid biopsy technology into Agilus’ laboratory network. The collaboration provides patients in India with access to genomic profiling for cancer detection and treatment selection.

• Technology: Integration of LiquidHALLMARK®, a next-generation sequencing assay that profiles 80 ctDNA genes and 37 ctRNA fusions to identify actionable biomarkers.
• Network Access: Molecular diagnostic services will be deployed throughout Agilus’ diagnostic centres to scale precision oncology coverage across the region.
• Clinical Application: The partnership introduces non-invasive genomic testing for early detection, therapy personalisation, and recurrence monitoring for the Indian healthcare market.

This summary is based on a press release issued by Lucence.